Jeremy Schafer

Articles

Is ICER’s Speed Coming at the Expense of Credibility?

The rapid pace of new pharmaceutical approvals raises questions of whether ICER can keep up and maintain the quality and rigor demanded by healthcare audiences, writes Jeremy Schafer.

Pricing in DTC: Adjusting to the New World

Strategies for pharma in delivering the full picture to patients.

Pricing in DTC: Adjusting to the New World

Pharmaceutical manufacturers should plan for a DTC strategy to minimize the risk of patient abandonment due to pricing concerns.